by FiveSenses | Jan 22, 2024 | Communiqué de presse
Vancouver, C.-B., Canada, 19 janvier 2024 – Defence Therapeutics Inc. (« Defence » ou la « Société »), (CSE : DTC, OTCQB : DTCFF, FSE : DTC), l’une des principales entreprises de biotechnologie canadiennes œuvrant dans le domaine de l’immuno-oncologie annonce, suite à... by FiveSenses | Jan 22, 2024 | News Release
Vancouver, BC, Canada, January 19th, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies working in the field of immune-oncology announces, further to its news... 
by FiveSenses | Jan 10, 2024 | News Release
Vancouver, BC, Canada, January 10th, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it... 
by FiveSenses | Jan 10, 2024 | Communiqué de presse
Vancouver, C.-B., Canada, 10 janvier 2024 – Defence Therapeutics Inc. (« Defence » ou la « Société »), (CSE : DTC, OTCQB : DTCFF, FSE : DTC), l’une des principales sociétés de biotechnologie canadiennes œuvrant dans le domaine de l’immuno-oncologie, est ravie...
Recent Comments